Weifa Proposes Separation of Consumer Health and B2B
![](/46/pdcnewsitem/03/43/11/VzTEpP54s2wKohe.jpg)
Weifa has announcedy that the Board of Directors will propose to separate the company’s consumer health and business-to-business ("B2B") operations through a sale of its B2B business and tablet production to Vistin Pharma, a newly established subsidiary of Weifa, which will seek listing on Oslo Axess.
A separation will allow the two companies to pursue their own strategic agenda, and represents a logical step in creating two companies with clear investment stories:
• Consumer Health — a pure consumer brand player with leading category positions
• Vistin Pharma — a strong pharmaceutical investment case with key positions and growth potential in the international metformin and opioids market, and a strong fundament to create a highly efficient Contract Management Organisation (CMO).
Highlights:
• Weifa is contemplating a sale of its B2B and tablet production (CMO) operations to the newly established company, Vistin Pharma
• Vistin Pharma will conduct an equity issue of approx. NOK 170 million to finance the B2B acquisition and secure working capital and funds for growth
• The equity issue is fully guaranteed by primarily large existing shareholders of Weifa
• All Weifa shareholders will receive tradable subscription rights in Vistin Pharma.
The board of Weifa considers that the proposed separation is in the best interests of both Weifa and Vistin Pharma, and will result in a stronger future for both the current consumer health and API activities of the Company. In particular, the board of Weifa considers that the profile and potential risks and rewards of Vistin Pharma, as an API company, will be better understood as a standalone listed business. Weifa will continue its focus as a consumer health company.
The current CEO of Weifa, Kjell-Erik Nordby, will be appointed CEO of Vistin Pharma. The board of Weifa considers that the separation is in the best interests of Weifa shareholders, and the board unanimously recommends shareholders to vote in favour of the separation at the general meeting to be held in mid-April, comments chairman Glen Ole Rødland of Weifa. "I look forward to collaborating with the board to further build upon the strong foundation set by Weifa. I am energized by the opportunity to continue leveraging the unique API facilities in Kragerø to expand the metformin, the opoids and the CMO businesses," comments CEO Kjell-Erik Nordby of Weifa.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance